(4-溴苯基)(1-哌嗪基)甲酮 | 59939-72-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-溴苯基)(1-哌嗪基)甲酮
• 英文名称: 1-(4-bromobenzoyl) piperazine
• 英文别名: (4-Bromophenyl)(piperazin-1-yl)methanone；(4-bromophenyl)-piperazin-1-ylmethanone
• CAS: 59939-72-9
• 化学式: C₁₁H₁₃BrN₂O
• mdl: MFCD09037861
• 分子量: 269.141
• InChiKey: WLJZWLGUPJDGIL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (4-溴苯基)(1-哌嗪基)甲酮 在 potassium carbonate 、 三氟乙酸 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 34.0h， 生成 2-(4-(4-bromobenzoyl)piperazin-1-yl)-1-(4-(3-(5-fluoro-1H-indol-3-yl)propyl)piperazin-1-yl)ethan-1-one
  参考文献：
  名称：

  Synthesis, in vitro evaluation and molecular docking of a new class of indolylpropyl benzamidopiperazines as dual AChE and SERT ligands for Alzheimer’s disease

  摘要：

  During the last decade, the one drug-one target strategy has resulted to be inefficient in facing diseases with complex ethiology like Alzheimer's disease and many others. In this context, the multitarget paradigm has emerged as a promising strategy. Based on this consideration, we aim to develop novel molecules as promiscuous ligands acting in two or more targets at the same time. For such purpose, a new series of indolylpropyl-piperazinyl oxoethyl-benzamido piperazines were synthesized and evaluated as multitarget-directed drugs for the serotonin transporter (SERT) and acetylcholinesterase (AChE). The ability to decrease beta-amyloid levels as well as cell toxicity of all compounds were also measured. In vitro results showed that at least four compounds displayed promising activity against SERT and AChE. Compounds 18 and 19 (IC50 = 3.4 and 3.6 mu M respectively) exhibited AChE inhibition profile in the same order of magnitude as donepezil (DPZ, IC50 = 2.17 mu M), also displaying nanomolar affinity in SERT. Moreover, compounds 17 and 24 displayed high SERT affinities (IC50 = 9.2 and 1.9 nM respectively) similar to the antidepressant citalopram, and significant micromolar AChE activity at the same time. All the bioactive compounds showed a low toxicity profile in the range of concentrations studied. Molecular docking allowed us to rationalize the binding mode of the synthesized compounds in both targets. In addition, we also show that compounds 11 and 25 exhibit significant beta-amyloid lowering activity in a cell-based assay, 11 (50% inhibition, 10 mu M) and 25 (35% inhibition, 10 mu M).These results suggest that indolylpropyl benzamidopiperazines based compounds constitute promising leads for a multitargeted approach for Alzheimers disease. (C) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2020.112368
• 作为产物：
  描述：

  4-(4-溴-苯甲酰基)-哌嗪-1-羧酸叔丁酯 在 三氟乙酸 作用下， 以 氯仿 为溶剂， 反应 8.0h， 生成 (4-溴苯基)(1-哌嗪基)甲酮
  参考文献：
  名称：

  恶唑并[4,5-b]吡啶基哌嗪酰胺作为 GSK-3β 抑制剂，具有减轻炎症和抑制促炎症介质的潜力

  摘要：

  最近的研究表明，糖原合酶激酶-3β (GSK-3β) 是一种促炎酶，通过抑制这种激酶，可以控制炎症。在这方面，合成了一系列 17 种哌嗪连接的恶唑并 [4,5-b] 吡啶基衍生物，并评估了体外 GSK-3β 抑制和体内抗炎活性。在所有合成的化合物中，化合物 7d、7e、7g 和 7c 显示出最好的 GSK-3β 抑制活性，相应的 IC50 值为 0.34、0.39、0.47 和 0.53 µM。在大鼠足爪水肿模型中检测了化合物 7d、7e、7g 和 7c 的体内抗炎活性，化合物 7d 表现出最大的抑制作用，在角叉菜胶给药后 3 和 5 小时，爪体积分别减少 62.79% 和 65.91%分别与吲哚美辛相比（3 小时和 79 小时为 76.74%。角叉菜胶给药后 5 小时为 54%）。此外，与吲哚美辛相比，这些化合物（7d、7e、7g 和 7c）还被发现在体外显着抑制促炎介质，即 TNF-α、IL-1β

  DOI：

  10.1002/ardp.201700022

文献信息

• Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists
  申请人：Mutahi W. Mwangi

  公开号：US20070167435A1

  公开（公告）日：2007-07-19

  Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein: M is CH or N; U and W are each CH, or one of U and W is CH and the other is N; X is a bond, alkylene, —C(O)—, —C(N—OR 5 )—, —C(N—OR 5 )—CH(R 6 )—, —CH(R 6 )—C(N—OR 5 )—, —O—, —OCH 2 —, —CH 2 O— or —S(O) 0-2 —; Y is —O—, —(CH 2 ) 2 —, —C(═O)—, —C(═NOR 7 )— or —SO 0-2 —; Z is a bond, optionally substituted alkylene or alkylene interrupted by a heteroatom or heterocyclic group; R 1 is optionally substituted alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocycloalkyl, or benzimidazolyl or a derivative thereof; R 2 is optionally substituted alkyl, alkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification; compositions and methods for treating an allergy-induced airway response, congestion, diabetes, obesity, an obesity-related disorder, metabolic syndrome and a cognition deficit disorder using said compounds, alone or in combination with other agents.

  揭示了以下化合物的结构式或其药学上可接受的盐或溶剂，其中：M为CH或N；U和W分别为CH，或者U和W中的一个为CH，另一个为N；X为键，烷基，—C(O)—，—C(N—OR5)—，—C(N—OR5)—CH(R6)—，—CH(R6)—C(N—OR5)—，—O—，—OCH2—，—CH2O—或—S(O)0-2—；Y为—O—，—(CH2)2—，—C(═O)—，—C(═NOR7)—或—SO0-2—；Z为键，可选择地取代的烷基或被杂原子或杂环基中断的烷基；R1为可选择地取代的烷基，环烷基，芳基，芳基烷基，杂芳基，杂环烷基或苯并咪唑基或其衍生物；R2为可选择地取代的烷基，烯基，芳基，芳基烷基，杂芳基，杂芳基烷基，环烷基或杂环烷基；其余变量如规范中所定义；使用这些化合物，单独或与其他药剂联合使用，治疗由过敏引起的气道反应、充血、糖尿病、肥胖症、与肥胖有关的疾病、代谢综合征和认知缺陷障碍的组合物和方法。
• New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20180044335A1

  公开（公告）日：2018-02-15

  The present invention encompasses compounds of general formula (I) wherein the groups R 1 to R 9 , X 1 and X 2 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, e.g. cancer, pharmaceutical preparations containing such compounds and their uses as a medicament.

  本发明涵盖了一般式（I）的化合物，其中基团R1至R9，X1和X2的含义如权利要求和说明书中所述。本发明的化合物适用于治疗由细胞过度或异常增殖所特征化的疾病，例如癌症，含有这种化合物的制药制剂以及它们作为药物的用途。
• Synthesis and positive inotropic evaluation of [1,2,4]triazolo[3,4-a]phthalazine and tetrazolo[5,1-a]phthalazine derivatives bearing substituted piperazine moieties
  作者：Long-Xu Ma、Bai-Ri Cui、Yan Wu、Jia-Chun Liu、Xun Cui、Li-Ping Liu、Hu-Ri Piao

  DOI：10.1016/j.bmcl.2014.02.040

  日期：2014.4

  Four series of [1,2,4]triazolo[3,4-]phthalazine and tetrazolo[5,1-]phthalazine derivatives bearing substituted piperazine moieties were synthesized and evaluated for their positive inotropic activity by measuring the left atrium stroke volume in isolated rabbit-heart preparations. Several compounds were developed and showed favorable activities compared to the standard drug milrinone, with (4-([1,2

  合成了四个系列的带有取代哌嗪部分的[1,2,4]三唑并[3,4-]酞嗪和四唑并[5,1-]酞嗪衍生物，并通过测量分离的左心房搏出量来评估其正性肌力活性。兔心制剂。与标准药物米力农相比，开发了几种化合物，并显示出良好的活性，其中（4-（[1,2,4]三唑并[3,4-]酞嗪-6-基）哌嗪-1-基）（-甲苯基）甲酮 () 被认为是最有效的，浓度为 3×10M 时每搏输出量增加 19.15±0.22%（米力农：2.46±0.07%）。作用机制初步研究表明其正性肌力作用可能与PDE-cAMP-PKA信号通路有关。还根据变时作用评价表现出正性肌力作用的化合物。
• Effective Formylation of Amines with Carbon Dioxide and Diphenylsilane Catalyzed by Chelating bis(<i>tz</i>NHC) Rhodium Complexes
  作者：Thanh V. Q. Nguyen、Woo-Jin Yoo、Shū Kobayashi

  DOI：10.1002/anie.201504072

  日期：2015.8.3

  (NHC=N‐heterocyclic carbene) have been synthesized and applied to the reductive formylation of amines using CO2 and Ph2SiH2. A rhodium‐based bis(tzNHC) complex (tz=1,2,3‐triazol‐5‐ylidene) was identified to be highly effective at a low catalyst loading and ambient temperature, and a wide substrate scope, including amines with reducible functional groups, were compatible.

  使用CO 2和氢硅烷对胺进行还原甲酰化是将CO 2引入有价值的有机化合物中的一种有吸引力的方法。然而，先前的系统需要高催化剂负载量或高温才能达到高效率，并且底物范围主要限于简单的胺。为了解决这些问题，已经合成了一系列烷基桥连的螯合双（NHC）铑配合物（NHC = N-杂环卡宾），并将其用于使用CO 2和Ph 2 SiH 2还原胺的甲酰化反应。铑基双（tz NHC）络合物（tz1,2,3-三唑-5亚基）在较低的催化剂负载量和环境温度下被认为是高效的，并且兼容广泛的底物范围，包括具有可还原官能团的胺。
• [EN] NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN<br/>[FR] NOUVEAUX COMPOSÉS ET COMPOSITIONS POUR L'INHIBITION DE FASN
  申请人：FORMA THERAPEUTICS INC

  公开号：WO2014164749A1

  公开（公告）日：2014-10-09

  The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes. An illustrative compound of the invention is shown below:

  本发明涉及用于抑制FASN的化合物和组合物，其合成、应用和解毒剂。本发明的一个示例化合物如下所示：